Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Department of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Henan Medical Key Laboratory of Molecular Imaging, Zhengzhou, Henan, People's Republic of China.
Eur J Radiol. 2020 Dec;133:109301. doi: 10.1016/j.ejrad.2020.109301. Epub 2020 Sep 24.
To investigate the midterm efficacy and prognostic evaluation of patients with diffuse large B-cell lymphoma (DLBCL) by three image analysis methods: International Harmonization Project (IHP), Deauville 5-Point Scale (5-PS) and Δ SUVmax criteria in F-FDG PET/CT.
This was a retrospective analysis of 141 patients with DLBCL. All patients were given 3-4 cycles of chemotherapy and F-FDG PET/CT. According to three criteria, the patients were divided into negative and positive groups, respectively. Statistical methods were used to assess the midterm efficacy and prognosis factors.
During the midterm follow-up, a total of 109 people achieved CR. Three methods showed statistically significant differences in OS and PFS for the interim PET/CT, and Δ SUVmax criterion was an independent risk factor for the prognosis of DLBCL patients.
In our research, IHP, 5-PS and Δ SUVmax criteria all had a significant predictive value, while Δ SUVmax criterion had more advantages in evaluating the midterm efficacy and predicting prognosis for patients with DLBCL in interim PET/CT. But it should be noticed that Δ SUVmax criterion needs more strict guidelines in multicenter trials. The optimal cutoff value of Δ SUVmax% we recommended was 81.54%, which helped to judge the midterm efficacy.
通过三种图像分析方法（国际 harmonization project[IHP]、Deauville 5 分评分法[5-PS]和ΔSUVmax 标准），研究氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（F-FDG PET/CT）在弥漫性大 B 细胞淋巴瘤（DLBCL）患者中的中期疗效和预后评估。
这是一项对 141 例 DLBCL 患者的回顾性分析。所有患者均接受 3-4 个周期的化疗和 F-FDG PET/CT 检查。根据三个标准，患者分别分为阴性和阳性组。统计学方法用于评估中期疗效和预后因素。
在中期随访期间，共有 109 人达到完全缓解。三种方法在中期 PET/CT 时的 OS 和 PFS 均有统计学差异，ΔSUVmax 标准是 DLBCL 患者预后的独立危险因素。
在我们的研究中，IHP、5-PS 和 ΔSUVmax 标准均具有显著的预测价值，而ΔSUVmax 标准在评估中期疗效和预测预后方面对 DLBCL 患者的中期 PET/CT 具有更多优势。但需要注意的是，ΔSUVmax 标准在多中心试验中需要更严格的指导方针。我们推荐的ΔSUVmax%最佳截断值为 81.54%，有助于判断中期疗效。
